Artegraft Collagen Vascular Graft
LeMaitre Vascular, Inc. · Decision date Oct 15, 2026
What did the FDA decide?
The FDA record for Artegraft Collagen Vascular Graft, PMA N16837/S040, is a 30-day notice under supplement reason "Process Change - Manufacturer/Sterilizer/Packager/Supplier." The listed change is an additional service supplier to perform routine bioburden testing on the graft. The device category is a tissue graft of 6mm and greater, specialty Cardiovascular, product code LXA, applicant LeMaitre Vascular, Inc. The decision is OK30, dated 2026-10-15.
The identifier ties this to the original PMA N16837 only through the shared PMA number; the record does not describe that original approval's scope or its manufacturing chain. It is a manufacturing notice, not a new approval of the whole system. The statement's reported purpose is bioburden testing by an added supplier; it is not independent evidence of safety or clinical effectiveness. Absent are the supplier's identity, testing methods, site details, and acceptance criteria.
FDA approval order statement
an additional service supplier to perform routine bioburden testing on the Artegraft Collagen Vascular Graft
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 15, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- N16837/S040
- Regulatory pathway
- PMA supplement
- Applicant
- LeMaitre Vascular, Inc.
- Product code
- LXA
- Decision code
- OK30
- Decision date
- Oct 15, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Tissue graft of 6mm and greater.
- Applicant
- LeMaitre Vascular, Inc.
- Product code
- LXA
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
N16837/S040 received
Application receipt date recorded by FDA.
N16837/S040 · FDA decision
30-Day Notice
Related devices and submissions
Explore the linked device profile
Other records with product code LXA
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Artegraft Collagen Vascular GraftN16837/S039 | LeMaitre Vascular, Inc. | PMA supplement | Sep 4, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
LeMaitre Vascular, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 63 Second Ave., Burlington, MA, 01803
Sources and methodology
- Original FDA record: N16837/S040
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records